CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

Polo Pureza, whose name translates from Spanish as "Polo Purity," was inducted into the Argentine Association of Polo Horse ...

Argentina's Polo Pureza's genes live on in genetically edited horses designed to outrun her, created by Kheiron biotech firm.

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago. These ...

The slow ramp-up may also give competitors more time to advance their own gene therapies, potentially eroding CRISPR's first-mover advantage in the market. What challenges does CRISPR face in the ...

Still, even if this does prove successful, that doesn’t mean that the pipeline will be. But it’s a huge factor in showing that, not only will the FDA approve a CRISPR/CAS9 treatment ...

President Donald Trump is taking significant steps to eliminate DEI programs at the federal level. A memo from the U.S. Office of Personnel Management, issued Tuesday evening, instructed that all ...

Scientists at Argentine biotech firm Kheiron have produced the world's first genetically edited horses using a technique called CRISPR-Cas9 ... which is what nature does, but we do it faster ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

For many years, cloned ponies have excelled in the prestigious equestrian sport of polo, and the sport has now taken a ...

While Morocco has yet to embrace genome editing, specifically CRISPR, early research is underway ... This means that the final product does not contain any foreign genes, which makes it more ...